Kupka Ellen, Hesselman Susanne, Gunnarsdóttir Jóhanna, Wikström Anna-Karin, Cluver Catherine, Tong Stephen, Hastie Roxanne, Bergman Lina
Department of Obstetrics and Gynecology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Research and Higher Education, Center for Clinical Research, Dalarna, Uppsala University, Region Dalarna, Falun, Sweden.
JAMA Netw Open. 2025 Feb 3;8(2):e2457828. doi: 10.1001/jamanetworkopen.2024.57828.
It is unclear whether a higher dose (150-160 mg) or a lower dose (75 mg) of aspirin should be used to prevent preeclampsia.
To compare the risk of preeclampsia and bleeding complications between women using 150 to 160 mg of aspirin and those using 75 mg of aspirin for preeclampsia prevention.
DESIGN, SETTING, AND PARTICIPANTS: This nationwide cohort study included 13 828 women giving birth at 22 weeks' gestation or later in Sweden between January 2017 and December 2020 who used low dose aspirin (75-160 mg) during pregnancy. Data were analyzed from October to November 2023.
The use of 150 to 160 mg or 75 mg of aspirin in pregnancy.
The main outcome was a preeclampsia diagnosis recorded in the maternal birth record at the time of hospital discharge. The main safety outcome was postpartum hemorrhage, defined as bleeding more than 1000 mL after delivery. Relative risks (RRs) and 95% CIs were estimated using a doubly robust inverse probability-weighted regression adjustment model controlling for background characteristics.
In the total cohort of 13 828 women, the mean (SD) age was 33.0 (5.5) years and 3003 women (21.7%) were nulliparous. Of the women, 4687 (33.9%) were prescribed 150 to 160 mg of aspirin, and 9141 (66.1%) were prescribed 75 mg of aspirin. A total of 10 635 women (76.9%) had at least 2 dispensed prescriptions of low-dose aspirin. Among women using 150 to 160 mg of aspirin, 443 (9.5%) developed preeclampsia compared with 812 (8.9%) of those using 75 mg of aspirin (adjusted RR [aRR], 1.07; 95% CI, 0.93-1.24). Additionally, the risk of postpartum hemorrhage between the groups was similar, with 326 women (6.9%) using 150 to 160 mg of aspirin experiencing a postpartum hemorrhage compared with 581 (6.4%) in the 75-mg group (aRR, 1.08; 95% CI, 0.90-1.30).
In this cohort study of 13 828 women, no difference was found in preeclampsia incidence or bleeding complications between those using 150 to 160 mg of aspirin vs 75 mg of aspirin during pregnancy for preeclampsia prevention. These findings suggest that either dose may be a reasonable choice when using aspirin to prevent preeclampsia. However, large randomized trials investigating aspirin dose in pregnancy are still needed.
目前尚不清楚预防子痫前期应使用较高剂量(150 - 160毫克)还是较低剂量(75毫克)的阿司匹林。
比较使用150至160毫克阿司匹林的女性与使用75毫克阿司匹林预防子痫前期的女性发生子痫前期和出血并发症的风险。
设计、背景和参与者:这项全国性队列研究纳入了2017年1月至2020年12月期间在瑞典妊娠22周及以后分娩的13828名女性,她们在孕期使用了低剂量阿司匹林(75 - 160毫克)。数据于2023年10月至11月进行分析。
孕期使用150至160毫克或75毫克阿司匹林。
主要结局是出院时产妇分娩记录中记录的子痫前期诊断。主要安全结局是产后出血,定义为分娩后出血超过1000毫升。使用双重稳健逆概率加权回归调整模型控制背景特征来估计相对风险(RRs)和95%置信区间(CIs)。
在13828名女性的总队列中,平均(标准差)年龄为33.0(5.5)岁,3003名女性(21.7%)为初产妇。其中,4687名女性(33.9%)被开具了150至160毫克的阿司匹林,9141名女性(66.1%)被开具了75毫克的阿司匹林。共有10635名女性(76.9%)至少有2次低剂量阿司匹林的配药处方。在使用150至160毫克阿司匹林的女性中,443名(9.5%)发生了子痫前期,而使用75毫克阿司匹林的女性中有812名(8.9%)发生子痫前期(调整后RR [aRR],1.07;95% CI,0.93 - 1.24)。此外,两组之间产后出血的风险相似,使用150至160毫克阿司匹林的326名女性(6.9%)发生了产后出血,而75毫克组中有581名(6.4%)发生产后出血(aRR,1.08;95% CI,0.90 - 1.30)。
在这项对13828名女性的队列研究中,孕期使用150至160毫克阿司匹林与75毫克阿司匹林预防子痫前期的女性在子痫前期发病率或出血并发症方面未发现差异。这些发现表明,在使用阿司匹林预防子痫前期时,两种剂量可能都是合理的选择。然而,仍需要大型随机试验来研究孕期阿司匹林的剂量。